DRAFT – not reviewed. Not for publication until checked by a medical expert and approved by the CannaQ owner.
CannaQ

CannaQ › Blog › Multiple sclerosis

DRAFT – not reviewed

Cannabinoids and multiple sclerosis: spasticity, pain and side effects

A 2022 Cochrane review of 25 randomised trials found moderate-certainty evidence for a short-term effect on spasticity with one THC/CBD spray, and much weaker evidence for other symptoms.

Multiple sclerosisEvidence type: Systematic review, randomised controlled trialLast checked: Status: draft, awaiting medical expert review

Key points

  • A 2022 Cochrane review included 25 randomised trials with 3,763 adults with multiple sclerosis (MS).[1]
  • Nabiximols, a mouth spray with equal amounts of THC and CBD, probably increases the number of people reporting an important reduction in perceived spasticity in the short term (moderate certainty).[1]
  • For chronic nerve pain and quality of life, the review authors were uncertain about any effect.[1]
  • Cannabinoids may slightly increase stopping treatment because of side effects, and may increase nervous-system and psychiatric side effects (low certainty).[1]

The symptoms in question

Spasticity (muscle stiffness and spasms) and chronic neuropathic pain are common and serious symptoms of MS. They tend to increase as the disease progresses, and the review notes that existing anti-spasticity medicines and painkillers are of limited benefit or poorly tolerated.[1]

The 2022 Cochrane review

The review searched the literature up to December 2021 and included randomised trials of any cannabinoid in adults with MS.[1] The 25 trials lasted 3 to 48 weeks. Thirteen tested nabiximols, seven tested synthetic cannabinoids that mimic THC, and others tested an oral THC extract, dronabinol or inhaled herbal cannabis.[1]

OutcomeResult vs placeboCertainty
Important reduction in spasticity (nabiximols)OR 2.51 (95% CI 1.56 to 4.04); about 216 more per 1,000 people reporting benefit; 5 trials, 1,143 participantsModerate
Substantial relief of chronic neuropathic painOnly one small trial (48 participants) of a synthetic cannabinoid; authors uncertain whether pain is reducedVery low
Global impression "much" or "very much" improvedOR 1.80 (95% CI 1.37 to 2.36); 8 trials, 1,215 participantsModerate
Health-related quality of lifeMay have little to no effect (SMD −0.08, 95% CI −0.17 to 0.02; 8 trials, 1,942 participants)Low
Stopping treatment because of side effectsOR 2.41 (95% CI 1.51 to 3.84); about 39 more per 1,000; 21 trials, 3,110 participantsLow
Serious adverse eventsLittle to no difference (OR 1.38, 95% CI 0.96 to 1.99; 20 trials)Low
Nervous-system side effectsMay increase (OR 2.61, 95% CI 1.53 to 4.44)Low
Psychiatric side effectsMay increase (OR 1.94, 95% CI 1.31 to 2.88)Low
Drug toleranceVery uncertainVery low

OR = odds ratio; SMD = standardised mean difference; CI = confidence interval. Source: abstract of the Cochrane review.[1]

The authors concluded that the overall certainty of the evidence is limited by the short duration of the included studies.[1]

A closer look at one trial design

A phase 3 trial published in 2011 used an "enriched" design.[2] All 572 people enrolled first received nabiximols as an add-on for 4 weeks without a comparison group. Only those whose spasticity improved by at least 20% (272 people) could go on, and 241 were then randomised to continue nabiximols or switch to placebo for 12 weeks. In that second phase, spasticity scores favoured nabiximols (P=0.0002), as did several secondary outcomes, including spasm frequency and sleep disturbance.[2]

The authors explain that this design limits the comparison to people likely to benefit.[2] That is useful for some questions, but it also means the results do not describe what happens across all people with MS spasticity. About half of those enrolled did not reach the 20% improvement in the first phase.[2]

Limits of the evidence

  • Most trials were short. Long-term benefits and harms are not well established.[1]
  • The clearest finding concerns one product (nabiximols) and one symptom (spasticity), and it rests on people's own ratings of their symptoms.[1]
  • Results for one cannabinoid product cannot be assumed to apply to others.
  • One review author reported research grants from GW Pharmaceuticals for preclinical work and related patents. This is disclosed in the review.[1]

Ongoing research

On 2026-11-17, ClinicalTrials.gov listed three recruiting phase 2 trials of cannabis or cannabidiol in MS. They include a comparison of THC and CBD and a study of how cannabidiol relates to sleep and pain.[3,4,5]

Medical disclaimer. Educational content only, not medical advice. Legal status varies by country. Consult a qualified healthcare professional. This article summarises published research. It does not recommend any treatment, product or dose, and it is not a substitute for advice from a healthcare professional who knows your situation.

References

All identifiers below were retrieved and checked on 2026-11-17 through PubMed E-utilities, the Europe PMC REST API and the ClinicalTrials.gov API v2.

  1. Filippini G, Minozzi S, Borrelli F, Cinquini M, Dwan K. Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis. Cochrane Database Syst Rev. 2022;5(5):CD013444. PMID: 35510826. DOI: 10.1002/14651858.CD013444.pub2.
  2. Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011;18(9):1122–1131. PMID: 21362108. DOI: 10.1111/j.1468-1331.2010.03328.x.
  3. ClinicalTrials.gov. Cannabis (THC vs. CBD) in Multiple Sclerosis. Phase 2; recruiting (checked 2026-11-17). NCT06261489.
  4. ClinicalTrials.gov. Cannabis as a Complementary Treatment in Multiple Sclerosis. Phase 2; recruiting (checked 2026-11-17). NCT05092191.
  5. ClinicalTrials.gov. Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype. Phase 2; recruiting (checked 2026-11-17). NCT05269628.
Review notes (internal, remove before publication): Figures come from the PubMed abstracts only. The 'about half did not reach 20% improvement' sentence is calculated from 272 of 572 (48%) responders. The point that the main finding rests on self-rated outcomes is an editorial inference from 'perceived severity' and needs reviewer confirmation. Author lists, volume and pages were checked against PubMed esummary on 2026-11-17. Europe PMC listed no retraction, correction or update for references 1–2.

← All articles · How CannaQ grades evidence